Pulmonx Overview
- Year Founded
-
1995
- Status
-
Public
- Employees
-
296
- Stock Symbol
-
LUNG
- Investments
-
2
- Share Price
-
$2.74
- (As of Thursday Closing)
Pulmonx General Information
Description
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
Contact Information
Website
www.pulmonx.comCorporate Office
- 700 Chesapeake Drive
- Redwood City, CA 94063
- United States
Corporate Office
- 700 Chesapeake Drive
- Redwood City, CA 94063
- United States
Pulmonx Stock Performance
As of 19-Nov-2026, Pulmonx’s stock price is $2.74. Its current market cap is $119M with 43.6M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.74 | $2.69 | $1.13 - $3.25 | $119M | 43.6M | 637K | -$1.01 |
Pulmonx Financials Summary
As of 30-Sep-2026, Pulmonx has a trailing 12-month revenue of $88.8M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 82,399 | 71,171 | 216,153 | 414,164 |
| Revenue | 88,775 | 90,497 | 83,789 | 68,675 |
| EBITDA | (38,325) | (51,819) | (55,955) | (61,060) |
| Net Income | (42,553) | (54,003) | (56,394) | (60,843) |
| Total Assets | 110,212 | 129,291 | 162,850 | 177,781 |
| Total Debt | 56,346 | 56,364 | 56,471 | 41,424 |
Pulmonx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pulmonx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Pulmonx Comparisons
Industry
Financing
Details
Pulmonx Competitors (5)
One of Pulmonx’s 5 competitors is Broncus Medical, a Formerly VC-backed company based in San Jose, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Broncus Medical | Formerly VC-backed | San Jose, CA | ||||
| Globus Medical | Formerly VC-backed | Audubon, PA | ||||
| Sanovas | Formerly VC-backed | Petaluma, CA | ||||
| Hill-Rom | Corporation | Essen, Germany | ||||
| ELITechGroup | Formerly PE-Backed | Puteaux, France |
Pulmonx Patents
Pulmonx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021322211-A1 | Methods, systems, and devices for analyzing lung imaging data to determine collateral ventilation | Active | 06-Aug-2020 | ||
| AU-2021322211-B2 | Methods, systems, and devices for analyzing lung imaging data to determine collateral ventilation | Active | 06-Aug-2020 | ||
| AU-2026257567-A1 | Methods, systems, and devices for analyzing lung imaging data to determine collateral ventilation | Pending | 06-Aug-2020 | ||
| EP-4192346-A1 | Methods, systems, and devices for analyzing lung imaging data to determine collateral ventilation | Pending | 06-Aug-2020 | ||
| EP-4192346-A4 | Methods, systems, and devices for analyzing lung imaging data to determine collateral ventilation | Pending | 06-Aug-2020 | G06T7/0012 |
Pulmonx Signals
Pulmonx Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Pulmonx Acquisitions (2)
Pulmonx’s most recent deal was a Merger/Acquisition with Aeris Therapeutics. The deal was made on 08-Jan-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aeris Therapeutics | 08-Jan-2015 | Merger/Acquisition | Therapeutic Devices | ||
| Emphasys Medical | 13-May-2009 | Merger/Acquisition | Other Devices and Supplies |
Pulmonx ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.53 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
Pulmonx FAQs
-
When was Pulmonx founded?
Pulmonx was founded in 1995.
-
Where is Pulmonx headquartered?
Pulmonx is headquartered in Redwood City, CA.
-
What is the size of Pulmonx?
Pulmonx has 296 total employees.
-
What industry is Pulmonx in?
Pulmonx’s primary industry is Other Devices and Supplies.
-
Is Pulmonx a private or public company?
Pulmonx is a Public company.
-
What is Pulmonx’s stock symbol?
The ticker symbol for Pulmonx is LUNG.
-
What is the current stock price of Pulmonx?
As of 19-Nov-2026 the stock price of Pulmonx is $2.74.
-
What is the current market cap of Pulmonx?
The current market capitalization of Pulmonx is $119M.
-
What is Pulmonx’s current revenue?
The trailing twelve month revenue for Pulmonx is $88.8M.
-
Who are Pulmonx’s competitors?
Broncus Medical, Globus Medical, Sanovas, Hill-Rom, and ELITechGroup are competitors of Pulmonx.
-
What is Pulmonx’s annual earnings per share (EPS)?
Pulmonx’s EPS for 12 months was -$1.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process